Lonza agrees to acquire InterHealth Nutraceuticals for $300m

Swiss ingredient provider Lonza has agreed to purchase US-based dietary supplement ingredient supplier InterHealth Nutraceuticals for $300m.

InterHealth is a portfolio firm of Kainos Capital, a Dallas-based private equity firm with a focus on the consumer products sector.

The deal will boost Lonza's speciality nutritional ingredients portfolio and offer several synergies. 

Lonza CEO Richard Ridinger was quoted Foodingredientfirst.com as saying: “With this acquisition, Lonza is taking a further step along our strategic path as a high-value supplier to the healthcare continuum.”

The purchase will have an immediate positive impact on Lonza's earnings.

InterHealth Nutraceuticals develops and sells speciality nutritional ingredients, which are used by food, beverage and dietary supplement manufacturers.

It manufactures more than15 ingredients, including UC-II, which is used in several dietary supplements sold in health food retail outlets.

With this acquisition, Lonza will enhance its nutritional lineup in the segments of sports nutrition and weight management.